Brief: Fosun Pharmaceutical's Subsidiary Signs Agreement With Palleon
19/12/2024 10:17
Dec 19 (Reuters) - Shanghai Fosun Pharmaceutical Group
Co Ltd 600196.SS :
* SAYS SUBSIDIARY SHANGHAI HENLIUS BIOTECH INC SIGNS
COLLABORATION
AND LICENSING AGREEMENT WITH PALLEON PHARMACEUTICALS INC
Source text
Further company coverage: 600196.SS
(Reporting by Beijing Newsroom)
((yukun.zhang@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln